13-Valent Pneumococcal Conjugate Vaccine Serotype Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pneumococcal conjugate vaccines, such as Prevnar, provide limited protection against serotypes 6A and 19A, which are significant causes of invasive pneumococcal disease and antibiotic-resistant strains, especially in infants and young children, due to inadequate immunogenic responses and reliance on serogroup cross-protection.
Innovation Solution
A 13-valent pneumococcal conjugate vaccine (13vPnC) is developed, incorporating polysaccharide-protein conjugates from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F of Streptococcus pneumoniae, conjugated to CRM 197 carrier protein, with an optional aluminum-based adjuvant, to enhance immunogenicity and provide broader coverage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a 7-valent pneumococcal conjugate vaccine is used, then coverage for serotypes 4, 6B, 9V, 14, 18C, 19F and 23F is provided, but protection against serotypes 6A and 19A is insufficient
Solution Approach 1:
The vaccine is divided into distinct serotype-specific components, with each polysaccharide-protein conjugate targeting a specific pneumococcal serotype. This segmentation allows the vaccine to provide targeted protection against multiple serotypes simultaneously, including the previously underrepresented 6A and 19A serotypes, thereby resolving the contradiction between coverage breadth and protection effectiveness.
Solution Approach 2:
The 13-valent conjugate vaccine formulation provides universal protection across multiple serotypes through a single vaccine product. By incorporating polysaccharide-protein conjugates from 13 different serotypes, the vaccine achieves multi-functionality, simultaneously protecting against both the traditional 7 serotypes and the additional 6 serotypes including 6A and 19A, thus eliminating the need for separate vaccines for different serotype groups.
2Reliability
If polysaccharide vaccines are used, then pneumococcal disease prevention is achieved in elderly adults and high-risk patients, but infants and young children respond poorly
Solution Approach 1:
A protein carrier (such as CRM197) is used as an intermediary to bridge the gap between polysaccharide antigens and the infant immune system. The protein carrier acts as a mediator that enhances the immunogenicity of the polysaccharide components, enabling infants and young children to mount effective immune responses against the pneumococcal serotypes, thus resolving the contradiction between reliable immunogenic response and age-appropriate effectiveness.
3Reliability
If serogroup cross-protection is relied upon, then decline of serotype 6A and 19A disease is expected, but a significant burden of disease will remain
Solution Approach 1:
The vaccine provides local quality protection by incorporating specific polysaccharide-protein conjugates for each serotype, including 6A and 19A. This serotype-specific targeting ensures that the immune response is specifically directed against these problematic serotypes, providing localized protection that goes beyond general serogroup cross-protection and resolves the contradiction between disease reduction and serotype-specific protection.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.